Background: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). Methods: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. Results: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). Conclusions: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020 / L. Naehrlich, A. Orenti, F. Dunlevy, I. Kasmi, S. Harutyunyan, A. Pfleger, S. Keegan, G. Daneau, G. Petrova, D. Tjesic-Drinkovic, P. Yiallouros, A. Bilkova, H.V. Olesen, P.-. Burgel, T. Parulava, F. Diamantea, A. Parniczky, E.F. McKone, M. Mei-Zahav, M. Salvatore, C. Colombo, E. Aleksejeva, K. Malakauskas, M. Schlesser, S. Fustik, O. Turcu, D. Zomer-van Ommen, A.S. Wathne, L. Wozniacki, L. Pereira, L. Pop, N. Kashirskaya, M. Rodic, H. Kayserova, U. Krivecs, P. Mondejar-Lopez, I. de Monestrol, D. Dogru, H. Makukh, R. Cosgriff, S. van Koningsbruggen-Rietschel, A. Jung, V. Bobrovnichy, I. Bambir, A.D. Vukic, P. Drevinek, M.M. Jr, H. Corvol, L. Lemonnier-Videau, E. Hatziagorou, G. Fletcher, R. Padoan, V. Gulmans, E. Bakkeheim, E. Kondratyeva, E. Amelina, E. Zhekaite, O. Simonova, M.D. Pastor-Vivero, A. Lindblad, Y. Gokdemir, S. Pekcan, K. Brownlee, E. McClenaghan, S. Carr, E. Lammertyn, A. Zolin, A. Fox, M. Krasnyk, J. Van Rens. - In: JOURNAL OF CYSTIC FIBROSIS. - ISSN 1569-1993. - 20:4(2021 Aug), pp. 566-577. [10.1016/j.jcf.2021.03.017]

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

A. Orenti;C. Colombo;A. Zolin;
2021-08

Abstract

Background: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). Methods: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. Results: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). Conclusions: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.
Covid-19; Cystic fibrosis; Epidemiology; Europe; Incidence; SARS-CoV-2
Settore MED/10 - Malattie dell'Apparato Respiratorio
Settore MED/01 - Statistica Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 983.5 kB
Formato Adobe PDF
983.5 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/864039
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact